# Pemigatinib (Pemazyre)

Source: https://ourhealthnetwork.com/drugs/pemigatinib
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Pemigatinib?

Pemigatinib (brand name: Pemazyre) is a kinase inhibitor. It is prescribed to treat cholangiocarcinoma.

## Brand names

Pemazyre

## Indications

Pemigatinib is primarily prescribed for the treatment of cholangiocarcinoma.

## Conditions treated

- [Cholangiocarcinoma](https://ourhealthnetwork.com/conditions/cholangiocarcinoma)

## Mechanism of action

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2 and 3 with IC 50 values of less than 2 nM. Pemigatinib also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3.

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

alopecia, constipation, diarrhea, dry eye, dysgeusia, fatigue, hyperphosphatemia, nail toxicity

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)